Seattle Genetics SGNTV-002 (Ovarian Cancer) - Clinical Trial
What is the Purpose of this Study?
If you agree to be in this study, you will:
- Be randomized, like the flip of a coin, to one of two study drug options:
Group A: tisotumab vedotin once every 3 weeks
Group B: tisotumab vedotin once a week for 3 weeks, followed by one week off
- Receive the study drug until your disease no longer responds to the study drug, side effects prevents further continuation of the study drug, or the study closes.
- Return for a follow-up visit 30 days after the end of the study drug treatment period.
- Long-term follow-up contact will be made every 12 weeks until the end of participation in the study.
Participation in this study is expected to last up to 3 years and will include 30 or more office visits to the clinic. The sponsor plans to close the study about 2 years after the last patient agrees to participate in the study.
Platinum-resistant ovarian cancer
Who Can Participate in the Study?
Adult females with platinum-resistant ovarian cancer
What is Involved?
We are doing this study to learn about the safety and effectiveness of the investigational drug tisotumab vedotin in platinum-resistant ovarian cancer. Tisotumab vedotin is an experimental drug that is designed to stick to cancer cells, so the drug can kill them. .